HALOG-E (halcinonide) by PharmaIN is corticosteroid hormone receptor agonists [moa]. First approved in 1980.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
HALOG-E (halcinonide) is a potent topical corticosteroid cream that works by activating corticosteroid hormone receptors to reduce inflammation and immune response in the skin. It is indicated for inflammatory and pruritic dermatological conditions requiring topical corticosteroid therapy. The product targets patients with moderate-to-severe dermatitis, eczema, and other inflammatory skin disorders.
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling contraction in brand team size and transition to generic defense strategies.
Corticosteroid Hormone Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HALOG-E offers limited career growth potential due to its approaching loss of exclusivity and minimal linked job openings. Professionals joining this product should expect roles focused on competitive defense, channel optimization, and portfolio transition rather than launch or expansion activities.
Worked on HALOG-E at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.